An already-available drug shows evidence of helping to increase the survival rate in patients with EGRF mutations of non-small cell lung cancer. — AFP
A pill has been shown to halve the risk of death from a certain type of lung cancer when taken daily after surgery to remove the tumour, according to clinical trial results presented on June 4 (2023).
The results were unveiled in Chicago, United States, at the largest annual conference of cancer specialists, hosted by the American Society for Clinical Oncology (ASCO).
Already a subscriber? Log in.
Unlock 30% Savings on Ad-Free Access Now!
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
